$RLAY News

Relay Therapeutics: Revitalized By Breast Cancer Program, But Competition Is Intense

Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $31

Canaccord Genuity Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target of $29

JP Morgan Initiates Coverage On Relay Therapeutics with Overweight Rating, Announces Price Target of $28

Relay Therapeutics (RLAY) is One of the Best AI Driven Biotech Stocks, Here is Why

Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

Guggenheim Maintains Buy on Relay Therapeutics, Raises Price Target to $26

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $28

Relay Therapeutics, Inc. (RLAY) Presents at ISSVA World Congress 2026: The Latest in Vascular Anomalies - Slideshow

Relay Therapeutics (RLAY) Is Up 6.9% After Follow-On Offering And Early Zovegalisib Data Release

Relay Therapeutics: Encouraging Data, Competitive Risks (Downgrade)

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies - Slideshow

Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $27

Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $21

Relay Therapeutics: Zovegalisib Is Becoming A Platform In Disguise

Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies Transcript

This Biotech's Drug Just Wiped The Floor With Forecasts

Relay Therapeutics Announces Proposed Public Offering of Common Stock